AICAR 50mg

Description:
AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) is not a peptide but a nucleotide derivative. It is an experimental compound that has gained attention in the field of research related to metabolic disorders and physical performance enhancement.

AICAR was initially developed as an activator of AMP-activated protein kinase (AMPK), an enzyme involved in cellular energy homeostasis. By activating AMPK, AICAR can simulate the effects of exercise on muscles, such as increasing glucose uptake and enhancing fatty acid oxidation. This has led to interest in its potential applications in treating conditions like obesity, diabetes, and metabolic syndrome.

Furthermore, AICAR has been studied for its effects on physical endurance and performance. It has been shown to improve endurance in animal studies by enhancing the ability of muscles to utilize glucose and increasing the number of mitochondria, the energy-producing structures within cells.

AICAR Research:
Research on AICAR has focused on its potential therapeutic applications, particularly in the treatment of metabolic disorders, cardiovascular diseases, and neurodegenerative conditions. Here are some key areas of AICAR research:

● Metabolic disorders: Research has demonstrated that AICAR can improve metabolic parameters in various metabolic disorders. In a study published in the journal Cell, researchers showed that AICAR treatment improved glucose homeostasis and increased insulin sensitivity in mice, leading to reduced blood glucose levels. Other studies have also shown that AICAR can enhance fatty acid oxidation and inhibit fat synthesis in adipose tissue, suggesting its potential for treating obesity and related metabolic disorders.
● Cardiovascular diseases: AICAR has been investigated for its cardioprotective effects. Studies have shown that AICAR treatment can protect against cardiac ischemia/reperfusion injury by reducing oxidative stress, inflammation, and apoptosis in cardiac cells. Additionally, AICAR has been found to improve endothelial function and promote angiogenesis, which may have implications for the treatment of cardiovascular diseases such as myocardial infarction and peripheral artery disease.
● Neurodegenerative diseases: AICAR has shown promise in neurodegenerative disease research. In a study published in the journal Cell, AICAR was found to activate AMPK and protect against neuronal damage in a mouse model of Huntington’s disease. Another study demonstrated that AICAR treatment improved cognitive function and reduced neuroinflammation in a mouse model of Alzheimer’s disease. These findings suggest that AICAR may have potential therapeutic applications in neurodegenerative disorders.
● Exercise performance and endurance: AICAR has been investigated for its potential as an exercise mimetic and enhancer of endurance performance. Animal studies have shown that AICAR administration can improve exercise capacity and increase endurance by activating AMPK and stimulating glucose uptake and fatty acid oxidation in skeletal muscle cells. However, it’s important to note that the use of AICAR for performance enhancement in human athletes is not approved and is considered unethical.